title: Central administration of a 5-HT2 receptor agonist and antagonist: lack of effect on rapid eye movement sleep and pgo waves.
abstract: Serotonin (5-HT) has a role in regulating behavioral state and controlling the production of ponto-geniculo-occipital (PGO) waves, though the exact mechanism of action is not known. The most prevailing explanation is that 5-HT exerts its influence on behavioral state and PGO waves by inhibiting and disinhibiting cholinergic cells in the pedunculopontine tegmentum (PPT) and laterodorsal tegmentum (LDT), which have been implicated in their generation. Recent work in rats has demonstrated 5-HT2 receptors on most cholinergic cells in PPT/LDT. We microinfused the relatively specific 5-HT2 agonist, DOI (1-(2,5-dimethoxy-4-iodophenyl)-2-aminopropane), the relatively specific 5-HT2 antagonist, ketanserin, and the nonspecific 5-HT antagonist, methysergide, locally into the peribrachial region of PPT in cats and monitored behavioral state and PGO waves. Neither drug significantly affected behavioral state or PGO wave activity. These results suggest that 5-HT2 receptors associated with cholinergic cells are minimally involved in the control of behavioral state and, together with the recent findings of others, suggest that 5-HT may not modulate PGO wave generation via direct action on cholinergic neurons in PPT/LDT, a departure from the long-held but minimally-tested view.
authors.affiliation: Laboratory for the Study of the Brain in Sleep, Department of Animal Biology, The School of Veterinary Medicine, The University of Pennsylvania, Philadelphia, PA 19104, USA. lsanford@vet.upenn.edu
authors.forename: L D
authors.initials: LD
authors.lastname: Sanford
authors.forename: W K
authors.initials: WK
authors.lastname: Hunt
authors.forename: R J
authors.initials: RJ
authors.lastname: Ross
authors.forename: A I
authors.initials: AI
authors.lastname: Pack
authors.forename: A R
authors.initials: AR
authors.lastname: Morrison
mesh_terms: D000704:Analysis of Variance; D000818:Animals; D001143:Arousal / Q000187:drug effects / Q000502:physiology; D002415:Cats; D004569:Electroencephalography; D005260:Female; D007650:Ketanserin / Q000494:pharmacology; D008784:Methysergide / Q000494:pharmacology; D011149:Pons / Q000378:metabolism*; D011985:Receptors, Serotonin / Q000378:metabolism*; D012702:Serotonin Antagonists / Q000494:pharmacology*; D012890:Sleep / Q000187:drug effects / Q000502:physiology; D012895:Sleep, REM / Q000187:drug effects* / Q000502:physiology*; D014851:Wakefulness / Q000187:drug effects / Q000502:physiology
chemical_list: D011985:Receptors, Serotonin; D012702:Serotonin Antagonists; D007650:Ketanserin; D008784:Methysergide